Controversy about the American Heart Association's support for Vytorin use, saying the Enhance study was too limited and patients not discontinue use of Vytorin. House Commerce committee to investigate lack of disclosure of ties of AHA to Vytorin makers. AHA receives $2 million from Merck and the joint venture that makes Vytorin. In the absence of Vytorin patients, can get Zocor in generic form for $6 for 30 days supply. Is Vytorin, if its not any better, a clever way of marketing a combination of Zocor and Zetia and touting its effectiveness over Zocor alone with a much higher price?